- Home
- ONEG vs EVAX Comparison
ONEG vs EVAX Comparison
Compare ONEG & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEG | EVAX |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | Hong Kong | Denmark |
| Employees | 26 | N/A |
| Industry | Homebuilding | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 32.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ONEG | EVAX |
|---|---|---|
| Price | $0.91 | $4.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 1.9M | 26.1K |
| Earning Date | 01-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $328.20 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $1.95 |
| 52 Week High | $14.95 | $12.15 |
Technical Indicators
Market Signals| Indicator | ONEG | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 34.63 | 49.28 |
| Support Level | N/A | $3.96 |
| Resistance Level | $2.36 | $4.65 |
| Average True Range (ATR) | 0.87 | 0.24 |
| MACD | -0.41 | -0.04 |
| Stochastic Oscillator | 1.30 | 28.71 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About EVAX Evaxion Biotech
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.